IDEX Corporation
IEX - NYSE - $216.92 ▲ +%0.95
-
Earnings Wed 29 Jul

IDEX opens the
books on Wednesday evening.

8 analysts' median target is $250[FMP target], stock is $217, +15.2% upside potential. After Q1 +12.4% EPS beat[FMP earnings], the stock moved +0.2%.

↓ summary below
Quick Take - in 40 seconds
B+
BUY Council 3/6 - Moonshot 47

B+ = MoonshotScore 47[9-pillar formula] + Council 3/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $903.3M[FMP est], EPS $2.12[FMP est]. 8 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$2.12 EPS Estimate Last year $2.10 - +2% YoY YoY
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q1 EPS +12.4% beat[FMP] but the stock +0.2% D+1[FMP D+1]. Sean Gillen promised $17.7M CapEx + a sequential decline in Q4 during the Q1 earnings call[Sean Gillen capex transcript].

Watchlist

5 metrics stand out this quarter.

3% Expectation / Guide

Full Year Organic Growth Guidance

full_year_organic_growth_guidance

For the full year 2026, we now expect organic growth in the 3% to 4% range, an increase over our original 1% to 2% organic growth guidance coming into the year.

"For the full year 2026, we now expect organic growth in the 3% to 4% range, an increase over our original 1% to 2% organic growth guidance coming into the year."

- Sean Gillen, Chief Financial Officer - Q1 FY26 Earnings Call - April 29, 2026
17% Investor Focus

Hst Order Growth Q1

hst_order_growth_q1

In HST, organic orders increased 17% and revenue grew 11% organically.

"In HST, organic orders increased 17% and revenue grew 11% organically."

- Sean Gillen, Chief Financial Officer - Q1 FY26 Earnings Call - April 29, 2026
9% Investor Focus

Fmt Order Growth

fmt_order_growth

Orders in the Fluid & Metering Technologies (FMT) segment grew 9% organically year-over-year, driven by strong order activity in our water platform and our pumps businesses.

"Finally, orders in our Fluid & Metering Technologies, or FMT segment, grew 9% organic year-over-year. This was driven by strong order activity in our water platform and our pumps businesses."

- Eric Ashleman, President and Chief Executive Officer - Q1 FY26 Earnings Call - April 29, 2026
2026 Expectation / Guide

Fy26 Guidance Increase

fy26_guidance_increase

IDEX is raising its full year 2026 financial outlook, taking into account Q1 performance and backlog build.

"Taking our Q1 performance and backlog build into account, we are raising our full year 2026 financial outlook."

- Eric Ashleman, President and Chief Executive Officer - Q1 FY26 Earnings Call - April 29, 2026
2026 Investor Focus

Share Repurchase Commitment

share_repurchase_commitment

IDEX plans on maintaining the share repurchase level per quarter through the rest of 2026.

"We plan on maintaining the share repurchase level per quarter through the rest of 2026."

- Sean Gillen, Chief Financial Officer - Q1 FY26 Earnings Call - April 29, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 47 / 100

9-pillar methodology. Cash Runway and Price Momentum strong. Revenue Growth weak.

How is it calculated? ->
Revenue Growth1.0Q1 vs Q2: growth slowing (+2.5%, below threshold)
Gross Margin4.0Q1: average margin (44.9%)
Operating Leverage2.0op margin healthy (19.4%)
Cash Runway10.0FCF very strong ($0.1B, 4.9x CapEx)
R&D Intensity3.0low R&D investment (0.0%, weak innovation)
Price Momentum7.0RSI 63.7 positive momentum, 50d above
News Sentiment6.0majority buy (56%)
Council Score 3 / 6 Bullish

6 investor frameworks. 3 bullish (Ray Dalio, Ken Griffin, Buffett), 0 bearish (none), 3 neutral (Jim Simons, Klarman, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +15.2%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 64
Klarman value - target upside +15.2%
Buffett quality - ROE score 4/5
Munger valuation - target upside +15.2%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
63.7 RSI 63.7 positive momentum, 50d above
MACD
+8.30 price above 50d - support positive
50d MA
$200 stock 8.3% above - short-term support
200d MA
$182 stock 19.1% above - long-term support
Volume (10d)
-28% decrease - low participation
Resistance
$250
Analyst median target - upgrade trigger if broken
Current
$217
Pre-earnings position
Support
$155
Invalidation - close below this is a technical breakdown
Pattern
Range
$155-$250 band - earnings breakout/breakdown trigger

Past Performance

IDEX beat expectations in the last 8 quarters.

BEAT
Q2 FY25
$2.07 vs $2.00 est - -0.5%
BEAT
Q3 FY25
$2.03 vs $1.93 est - -1.8%
BEAT
Q4 FY25
$2.10 vs $2.04 est - +0.3%
BEAT
Q1 FY26
$2.00 vs $1.78 est - +0.2%

Q1 (April 29, 2026): EPS $2.00 vs $1.78 est[FMP], +12.4% beat. D+1 movement: +0.2%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $2.06 (no guidance)

Q1: EPS $2.00 vs $1.78 beat[FMP], stock +0.2% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $17.7M[FMP cashflow]. Q1 op margin 19.4%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $2.12 + CapEx discipline
Threshold: EPS > $2.12[FMP est].
Target: Break above median target $250[FMP target]; high target $257[FMP] upper bound.
Scenario B - In-Line
EPS approx $2.12 + CapEx < $17.7M
Threshold: EPS approx $2.12[FMP est], Q4 CapEx < $17.7M[FMP].
Target: Consolidation in the band between current $217[FMP] and median $250[FMP].
Scenario C - Miss
EPS < $2.06 or CapEx >= $17.7M
Threshold: EPS < $2.06[FMP estx0.97].
Target: Current $217 below SMA200 $182[FMP], if rejection continues, $155[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 8 analysts say?

Wall Street Consensus
$250
12-month median target price (+15.2% upside potential)
9
BUY
7
HOLD
0
SELL
Risk Management
$155
Invalidation level - critical support threshold
$200 - 50-day MA (above, +8.3%)
$182 - 200-day MA (above, +19.1%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - IEX Q4 FY26
B+

You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Wednesday evening. The framework is ready on this page: Q4 EPS threshold $2.12[FMP], CapEx threshold "below $17.7M"[Sean Gillen]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days IEX dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 29, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 30, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 12, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 29, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the IEX earnings preview cover?

This IEX (IEX) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in IEX earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.